Physician
Oncology
Dr. Nuhad K. Ibrahim, MD
|
|
Give Review
Nuhad Ibrahim practices Oncology. He studied medicine at University of Baghdad College of Medicine. He received awards:"Fellow (FACP)". Doctor Nuhad K. Ibrahim, MD is a published doctor and has 84 publications published. The lastest was: 'Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol.' Dr. Nuhad K. Ibrahim accepts all Medicare patients.
Publications
- Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast C...
- Risk stratification in patients with advanced-stage Breast cancer by pretreatment [(18) F]FDG PET/CT.
- Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.
- Breast Cancer With Brain Metastases: Clinicopathologic Features, Survival, and Paired Biomarker Analysis.
- Open label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC vs. the combination of paclitaxel and everolimus followed by ...
- Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis.
- Outcome of metastatic Breast cancer in selected women with or without deleterious BRCA mutations.
- Elevated serum P1NP predicts development of bone metastasis and survival in early-stage Breast cancer.
- MUC1 glycopeptide epitopes predicted by computational glycomics.
- Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients with Advanced Solid Tumors.
- Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor-positive Locally Advanced or Metastatic Breast Cancer.
- Immunologic mapping of glycomes: implications for Cancer diagnosis and therapy.
- Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in Breast cancer.
- Molecular anatomy of Breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.
- A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic Breast c...
- Nomogram to predict subsequent brain metastasis in patients with metastatic Breast cancer.
- Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth fact...
- The impact of immediate Breast reconstruction on the technical delivery of postmastectomy radiotherapy.
- Aromatase inhibitors in Breast cancer: an overview.
- Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic Breast cancer.
- Weekly paclitaxel improves pathologic complete remission in operable Breast cancer when compared with paclitaxel once every 3 weeks.
- Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized tr...
- Colitis in patients with breast Carcinoma treated with taxane-based chemotherapy.
- Leukemogenic effect of chemotherapy in patients with breast Carcinoma: is it a real concern?
- Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast Carcinoma.
- Clinical development of the STn-KLH vaccine (Theratope).
- A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic Breast cancer.
- Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor ...
- Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable Breast cancer: preliminary data of a prospective randomized trial.
- Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
- Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic Breast cancer.
- Ixabepilone development across the Breast cancer continuum: a paradigm shift.
- Nanoparticle albumin-bound paclitaxel for treatment of metastatic Breast cancer.
- Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic Breast cancer.
- Phase I study of prolonged-infusion gemcitabine combined with cyclophosphamide in patients with metastatic Carcinoma of the breast: tolerability of an optimal dose sch...
- Radiologic findings in taxane induced colitis.
- Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast Carcinoma.
- A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic Breast cancer.
- Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer Cells and its biologic effects: a phase I clinical trial.
- Phase I study of vinorelbine by 96-hour infusion in advanced metastatic Breast cancer.
- Doxorubicin-based adjuvant chemotherapy in elderly Breast cancer patients: the M.D. Anderson experience, with long-term follow-up.
- Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast Carcinoma.
- Commentary on "A review of vinorelbine in the treatment of Breast cancer".
- Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy.
- The University of Texas M.D. Anderson Cancer Center experience with paclitaxel in Breast cancer.
- Hand-foot syndrome following prolonged infusion of high doses of vinorelbine.
- Doxorubicin-induced congestive heart failure in elderly patients with metastatic Breast cancer, with long-term follow-up: the M.D. Anderson experience.
- Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast Carcinoma.
- Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with opera...
- US-guided implantation of metallic markers for permanent localization of the tumor bed in patients with Breast cancer who undergo preoperative chemotherapy.
- Colitis associated with docetaxel-based chemotherapy in patients with metastatic Breast cancer.
- Defining prognosis for women with Breast cancer and CNS metastases by HER2 status.
- Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in Breast cancer.
- Doxorubicin-based chemotherapy in elderly patients with metastatic Breast cancer. Tolerance and outcome.
- Paclitaxel-containing combination chemotherapy for metastatic Breast cancer.
- Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic Cancers.
- Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study.
- Breast cancer molecular subtypes respond differently to preoperative chemotherapy.
- Paclitaxel in the multimodality treatment for inflammatory breast Carcinoma.
- Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer Cells highly resistant to taxol.
- Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in Breast cancer.
- Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced Breast cancer.
- Aromatase inhibitors: current status.
- The evolving role of specific estrogen receptor modulators (SERMs)
- Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on Breast cancer.
- Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic Breast cancer: cumulative toxicities limit dose escalation.
- Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced Breast cancer: long-term results.
- Canalicular stenosis Secondary to weekly docetaxel: a potentially preventable side effect.
- Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic Breast cancer.
- New antiestrogens in Breast cancer: a review.
- A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive Breast cancer.
- Therapeutic Breast cancer vaccines: a new strategy for early-stage disease.
- Albumin-bound Paclitaxel in metastatic Breast cancer: viewpoints.
- Colorectal adenoCarcinoma in young Lebanese adults. The American University of Beirut-Medical Center experience with 32 patients.
- Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small Cell lung cancer.
- An epidemiological study on survival of oropharyngeal Cancer cases in Alexandria, Egypt.
- VP-16-based regimen in adult acute nonlymphoblastic Leukemia.
- Efficacy of continuous high-dose metoclopramide in patients receiving daily cisplatin infusions.
- Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial.
- Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer Cells.
- Non-Hodgkin's Lymphomas in the Middle East. A study of 417 patients with emphasis on special features.
- Primary small intestinal Lymphoma in adults. A comparative study of IPSID versus non-IPSID in the Middle East.
- Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature.
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Anemia
- Basal Cell Carcinoma
- Breast Cancer
- Carcinoma in Situ
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Amerigroup (Wellpoint)
- Blue Card PPO
- Blue Choice
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- First Health (Coventry Health Care) PPO
- Golden Rule
- GEHA
- Health Alliance
- HealthSmart
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- MVP Health Care
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- Fellow (FACP)
Education
-
University of Texas Health Science Center -
St Luke's-Roosevelt Hospital Center -
SUNY Health Science Center at Brooklyn -
University of Baghdad College of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1528153715 | |
| NPPES Provider LastName | IBRAHIM | |
| NPPES Provider FirstName | NUHAD | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 416.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 30.0 | |
| Percent Opioid Claims | 7.21 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1528153715 |
| Last Name Of The Provider | IBRAHIM |
| First Name Of The Provider | NUHAD |
| View All |
Similar Doctors
|
Dr. Putao Cen, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Larry W. Kwak, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Agop Y. Bedikian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Francesco Turturro, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michelle A. Fanale, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Banu K. Arun, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Waun K. Hong, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Jacqueline S. Hart, MD |